Ipsen SA
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more
Ipsen SA (IPN) - Total Assets
Latest total assets as of June 2025: €6.83 Billion EUR
Based on the latest financial reports, Ipsen SA (IPN) holds total assets worth €6.83 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Ipsen SA - Total Assets Trend (2002–2024)
This chart illustrates how Ipsen SA’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Ipsen SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Ipsen SA's total assets of €6.83 Billion consist of 31.4% current assets and 68.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.5% |
| Accounts Receivable | €697.20 Million | 10.8% |
| Inventory | €285.50 Million | 4.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.52 Billion | 39.1% |
| Goodwill | €699.50 Million | 10.9% |
Asset Composition Trend (2002–2024)
This chart illustrates how Ipsen SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ipsen SA's current assets represent 31.4% of total assets in 2024, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 10.5% of total assets in 2024, up from 0.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 42.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 39.1% of total assets.
Ipsen SA Competitors by Total Assets
Key competitors of Ipsen SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Ipsen SA - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Ipsen SA generates 0.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Ipsen SA generates $5.37 in net profit.
Ipsen SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.98 | 1.14 | 1.06 |
| Quick Ratio | 1.79 | 0.98 | 0.89 |
| Cash Ratio | 1.02 | 0.29 | 0.00 |
| Working Capital | €1.40 Billion | € 234.60 Million | € 76.00 Million |
Ipsen SA - Advanced Valuation Insights
This section examines the relationship between Ipsen SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.47 |
| Latest Market Cap to Assets Ratio | 0.63 |
| Asset Growth Rate (YoY) | 1.8% |
| Total Assets | €6.44 Billion |
| Market Capitalization | $4.04 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Ipsen SA's assets below their book value (0.63 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ipsen SA's assets grew by 1.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ipsen SA (2002–2024)
The table below shows the annual total assets of Ipsen SA from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €6.44 Billion | +1.84% |
| 2023-12-31 | €6.32 Billion | +12.75% |
| 2022-12-31 | €5.61 Billion | +12.37% |
| 2021-12-31 | €4.99 Billion | +15.71% |
| 2020-12-31 | €4.31 Billion | +0.14% |
| 2019-12-31 | €4.31 Billion | +27.52% |
| 2018-12-31 | €3.38 Billion | +9.94% |
| 2017-12-31 | €3.07 Billion | +26.76% |
| 2016-12-31 | €2.42 Billion | +25.05% |
| 2015-12-31 | €1.94 Billion | +13.12% |
| 2014-12-31 | €1.71 Billion | +9.46% |
| 2013-12-31 | €1.57 Billion | +0.27% |
| 2012-12-31 | €1.56 Billion | -4.43% |
| 2011-12-31 | €1.63 Billion | -2.67% |
| 2010-12-31 | €1.68 Billion | +6.43% |
| 2009-12-31 | €1.58 Billion | +0.45% |
| 2008-12-31 | €1.57 Billion | +18.66% |
| 2007-12-31 | €1.32 Billion | +8.95% |
| 2006-12-31 | €1.21 Billion | +28.83% |
| 2005-12-31 | €942.51 Million | +52.09% |
| 2004-12-31 | €619.71 Million | -6.94% |
| 2003-12-31 | €665.90 Million | +0.54% |
| 2002-12-31 | €662.33 Million | -- |